Newsroom | Gilead - Gilead Sciences
Gilead Signs Royalty-Free Voluntary Licensing Agreements with Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries. September 12, 2024.
Gilead Sciences Expands Liver Portfolio With Acquisition of …
Feb 12, 2024 · The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment …
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead …
Jan 22, 2024 · EVOKE-01 is evaluating Trodelvy ® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Gilead Strengthens Early Pipeline in Oncology and Inflammation …
May 9, 2023 · Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year.
Gilead and Assembly Biosciences Establish Partnership to Develop …
October 17, 2023. Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases. Back. ––Partnership combines Gilead’s proven track record and mission to develop transformative therapeutics targeting serious viral diseases, with Assembly Bio’s expertise and focus on antiviral R ...
Gilead Sciences
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial. September 12, 2024. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies. September 10, 2024.
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV ...
Sep 12, 2024 · This could support the initial launch of the first and only twice-yearly HIV prevention choice in 2025. Gilead is executing an access strategy that prioritizes speed and enables the most efficient paths for the regulatory review and approval of lenacapavir for PrEP in regions around the world.
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
Feb 6, 2024 · Sales were impacted by unfavorable pricing dynamics, offset by higher demand across chronic hepatitis C virus (“HCV”) and chronic hepatitis delta virus (“HDV”) products. Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.
Full Efficacy and Safety Results for Gilead ... - Gilead Sciences
Jul 24, 2024 · Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at birth).
Gilead Sciences Announces Fourth Quarter and Full Year 2022 …
Feb 2, 2023 · Fourth Quarter 2022 Financial Results. Total fourth quarter 2022 revenue of $7.4 billion increased 2% compared to the same period in 2021, primarily due to increased sales in Oncology, HIV and hepatitis C virus (“HCV”), partially offset by lower Veklury® (remdesivir) sales.
- Some results have been removed